Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 3, 2007, Pages 257-264

  Szajewska, H ^a   Skorka A ^a   Dylag, M ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROBIOTIC AGENT;

ACUTE DIARRHEA; ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; COMPARATIVE STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; EMBASE; FECES ANALYSIS; HUMAN; INFECTIOUS DIARRHEA; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZATION; RISK REDUCTION; SACCHAROMYCES BOULARDII; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING;

CHILD; CHILD, PRESCHOOL; DIARRHEA; HUMANS; INFANT; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS; SACCHAROMYCES; TREATMENT OUTCOME;

EID: 33846287913     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03202.x     Document Type: Article

References (31)

1. WHO. The Treatment of Diarrhea. A Manual for Physicians and other Senior Health Workers; WHO/CDR/95.3. Geneva: World Health Organization, 1995.
2. Riedel BD, Ghishan FK. Acute diarrhea. In: Walker WA, Durie PR, Hamilton JR, Walker-Smith JA, Watkins JB, eds. Pediatric Gastrointestinal Disease, 2nd edn. St Louis: Mosby-Year Book Inc., 1996: 251-62.
3. Guarner F, Schaafsma GJ. Probiotics. Int J Food Microbiol 1998; 39: 237-8.
4. Van Niel C, Feudtner C, Garrison MM, Christakis DA. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics 2002; 109: 678-84.
5. Huang JS, Bousvaros A, Lee JW, et al. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci 2002; 47: 2625-34.
6. Allen SJ, Okoko B, Martinez E, et al. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2003 (issue 4). Art. No.: CD003048.pub2. DOI: 10.1002/14651858.CD003048.pub2.
7. Szajewska H, Mrukowicz J. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo controlled trials. J Pediatr Gastroenterol Nutr 2001; 33: S17-25.
8. Rodrigues AC, Nardi RM, Bambirra EA, Vieira EC, Nicoli JR. Effect of Saccharomyces boulardii against experimental oral infection with Salmonella typhimurium and Shigella flexneri in conventional and gnotobiotic mice. J Appl Bacteriol 1996; 81: 251-6.
9. Czerucka D, Rampal P. Effect of Saccharomyces boulardii on cAMP- and Ca2+-dependent Cl- secretion in T84 cells. Dig Dis Sci 1999; 44: 2359-68.
10. Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P. Implication of mitogen-activated protein kinases in T84 cell responses to enteropathogenic Escherichia coli infection. Infect Immun 2001; 69: 1298-305.
11. Pothoulakis C, Kelly CP, Joshi MA, et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993; 104: 1108-15.
12. Brandao RL, Castro IM, Bambirra EA, et al. Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae. Appl Environ Microbiol 1998; 64: 564-8.
13. Buts JP, Bernasconi P, Vaerman JP, Dive C. Stimulation of secretory IgA and secretory component of immunoglobulin in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 1990; 35: 251-6.
14. Qamar A, Aboudola S, Warny M, et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 2001; 69: 2762-5.
15. Sougioultzis S, Simeonidis S, Bhaskar KR, et al. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun 2006; 343: 69-76.
16. Szajewska H, Mrukowicz J. Meta-analysis: Non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic associated diarrhoea. Aliment Pharmacol Ther 2005; 22: 365-72.
17. Hafeez A, Tariq P, Ali S, Kundi ZU, Khan A, Hassan M. The efficacy of Saccharomyces boulardii in the treatment of acute watery diarrhea in children: a multicentre randomized controlled trial. J Coll Physicians Surg Pak 2002; 12: 432-4.
18. Higgins JPT, Green S., editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.4 [updated March 2005]. In: The Cochrane Library, Issue 2. Chichester, UK: John Wiley & Sons, Ltd, 2005.
19. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-34.
20. Villarruel G, Rubio DM, Lopez F, Cintioni J, Gurevech R, Romero G. Saccharomyces boulardii in acute childhood diarrhea: a randomized controlled study. (In press).
21. Billoo AG, Memon MA, Khaskheli SA, et al. Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World J Gastroenterol 2006; 12: 4557-60.
22. Kurugol Z, Koturoglu G. Effects of Saccharomyces boulardii in children with acute diarrhoea. Acta Paediatr 2005; 94: 44-7.
23. Cetina-Sauri G, Busto GS. Therapeutic evaluation of Saccharomyces boulardii in children with acute diarrhea. Ann Ped 1994; 6: 397-400.
24. Chapoy P. Treatment of acute infantile diarrhea: controlled trial of Saccharomyces boulardii. Ann Pediatr (Paris) 1985; 32: 561-3 (French).
25. Urganci N, Polat T, Uysalol M, Cetinkaya F. Evaluation of the efficacy of Saccharomyces boulardii in children with acute diarrhoea. Arch Gastroenterohepatol 2001; 20: 1-6.
26. Hochter W, Chase D, Hagenhoff G. Saccharomyces boulardii in acute adult diarrhea. Efficacy and tolerance of treatment. Münch Med Wochen 1990; 132: 188-92.
27. Human Development Report 2004. Available at: http://hdr.undp.org. (Last accessed October 2006).
28. World Health Organization. The Rational Use of Drugs in the Management of Acute Diarrhoea in Children. Geneva, Switzerland: World Health Organization, 1990.
29. Bassetti S, Frei R, Zimmerli W. Fungemia with Saccharomyces cerevisiae after treatment with S. boulardii. Am J Med 1998; 105: 71-2.
30. Rijnders BJA, Van Wijngaerden E, Verwaest C, Peetermans WE. Saccharomyces fungemia complicating S. boulardii treatment in a non-immunocompromised host. Intensive Care Med 2000; 26: 825.
31. Zunic P, Lacotte J, Pegoix M, et al. S. boulardii fungemia. Apropos of a case. Therapie 1991; 46: 498-9.